News from wuxi biologics A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Apr 27, 2022, 20:30 ET WuXi Biologics' 2021 ESG Report Reveals Company's Strong Commitment to Overall Sustainability

- WuXi Biologics has aligned its ESG strategy with the United Nations Sustainable Development Goals (SDGs), as well as with its stakeholders'...

Mar 22, 2022, 12:38 ET WuXi Biologics Achieved Record Growth and Profitability in 2021

Banner Year for Commercial Manufacturing Revenue Increased by 83.3% Y-o-Y to RMB10,290.1 Million Gross Profit Increased by 90.6% Y-o-Y to RMB4,828.9...

Mar 14, 2022, 08:30 ET WuXi Biologics Recognized as 2022 Top-Rated ESG Company by Sustainalytics

WuXi Biologics ("WuXi Bio") (2269.HK), a global CRDMO service company, has been recognized as the Industry Top-Rated Company in 2022 by...

Mar 01, 2022, 21:07 ET WuXi Biologics Wins CMO Leadership Awards in All Six Core Categories for Fifth Consecutive Year

WuXi Biologics ("WuXi Bio") (2269.HK), a global CRDMO service company, today announced that the company has won the 2022 CMO Leadership Awards in all ...

Feb 07, 2022, 22:04 ET WuXi Biologics Statement

We have been made aware of a recent U.S. Commerce Department announcement that two WuXi Biologics (Cayman) subsidiaries in Shanghai and Wuxi will be...

Jan 17, 2022, 21:50 ET WuXi Biologics Completes GMP Inspection by South Korea's Ministry of Food and Drug Safety for Drug Substance Facility

WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platforms, announced that it has completed a...

Dec 27, 2021, 19:30 ET WuXi Biologics and ImmuneOncia Sign MOU for Development and Manufacturing of Anti-PD-L1/CD47 Bispecific Antibody

WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platforms, and ImmuneOncia Therapeutics, Inc.,...

Oct 27, 2021, 20:30 ET WuXi Biologics Completes GMP Inspection by Health Canada for Drug Substance Facility

WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platforms, announced that it has completed a...

Sep 01, 2021, 02:00 ET WuXi Biologics Received First Manufacturing License from Japan and Completed 12 Global Regulatory Inspections in 2021 Year to Date

WuXi Biologics (WuXi Bio) (2269.HK), a global company with leading open-access biologics technology platforms, today announced that it has received...

Aug 23, 2021, 08:47 ET WuXi Biologics Reports Strong 2021 Interim Results

Revenue Increases by 126.7% Y-o-Y to RMB4,406.8 Million Gross Profit Grows by 191.7% Y-o-Y to RMB2,296.8 Million Adjusted Net Profit Attributable to...

Aug 02, 2021, 08:09 ET WuXi Biologics Biosafety Testing Facility Received Second EMA GMP Certificate

WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platforms, announced that only 13 months after...

Jul 27, 2021, 09:17 ET WuXi Biologics erhält von den deutschen Gesundheitsbehörden die Lizenz zur kommerziellen Herstellung von Arzneimitteln in Deutschland

Jul 26, 2021, 09:44 ET WuXi Biologics ha recibido una licencia de fabricación comercial de las autoridades sanitarias alemanas

Jun 09, 2021, 20:30 ET WuXi XDC and LegoChem Biosciences Signed Memorandum of Understanding for the Development and Manufacturing of Antibody-drug Conjugates

WuXi XDC ("XDC"), a global CDMO company dedicated to end-to-end bioconjugates services, and LegoChem Biosciences (141080KS, "LCB"), today announced...

May 26, 2021, 20:30 ET WuXi Biologics and OncoC4 Establish Exclusive CDMO Partnership

WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platforms, and OncoC4, Inc., a privately-held,...

May 13, 2021, 20:30 ET WuXi Biologics and WuXi STA Jointly Established WuXi XDC to Provide Fully Integrated Bioconjugate CDMO Services

WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platforms, and WuXi STA, a subsidiary of WuXi...

Apr 13, 2021, 05:00 ET WuXi Biologics Receives 2021 Asia-Pacific Bioprocessing Excellence Award from IMAPAC

WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platforms, announced that it has been...

Apr 06, 2021, 20:13 ET WuXi Biologics Successfully Completed Pre-License Inspection and Routine GMP Inspection by U.S. FDA

WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platforms, today announced that it has...

Mar 23, 2021, 08:59 ET 2020 Results Record High Despite a Challenging Year

Revenue Increased by 40.9% Y-o-Y to RMB5,612 Million Gross Profit Rose by 52.7% Y-o-Y to RMB2,533 Million Net Profit Grew by 67.5% Y-o-Y to RMB1,693...

Mar 17, 2021, 20:59 ET WuXi Biologics to Acquire CMAB and Form Strategic Partnership with CBC Group

WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platforms, today announced it has entered into...

Mar 17, 2021, 06:28 ET WuXi Vaccines franchit une étape importante dans la construction à l'épreuve des intempéries dans le bâtiment principal de l'usine de fabrication, malgré le COVID-19